ClinicalTrials.gg
Status unknownNCT04073680Updated May 21, 2020

A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors

A Phase 1/2 interventional study of Serabelisib and Canagliflozin 300mg in Breast Cancer, Endometrial Cancer and Lung Cancer, sponsored by Petra Pharma. Status unknown. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-21.

Sponsored by Petra Pharma · Phase 1/2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2020), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to test the hypothesis that combining serabelisib, a PI3K alpha isoform inhibitor, with an SGLT2 inhibitor, canagliflozin will improve efficacy in the treatment of patients with advanced solid tumors.

Read the detailed description

This study aims to test the hypothesis that controlling the glucose/insulin feedback will enhance the efficacy of PI3K inhibition in treating solid tumors. The treatment consists of serabelisib, a PI3K alpha isoform (PI3Kα) inhibitor, combined with the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin. The study will assess the safety and efficacy of the combination in adult patients with advanced solid tumors harboring mutations that may be dependent on PI3Kα activity: PIK3CA mutations and KRAS mutations.

02

Conditions studied

  • Breast Cancer
  • Endometrial Cancer
  • Lung Cancer
  • Colo-rectal Cancer
  • Head and Neck Cancer
03

In context

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

This study's planned enrollment of 60 is below the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

This is the only study on the registry with Petra Pharma as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have or cytologically confirmed locally advanced or solid tumors.
  2. Have a tumor harboring a mutation in PIK3CA or KRAS genes.
  3. Have received prior therapy and have recurrent or persistent disease without standard therapies available, or are ineligible to receive standard therapies.
  4. Have as defined by (RECIST) Version 1.1
  5. Have performance status (ECOG PS) of ≤2
  6. Have adequate organ function.
  7. Have adequate during the course of the study.
  1. Are able to receive canagliflozin

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of primary brain tumor
  2. Untreated or history of
  3. Have received prior chemotherapy within 28 days or other anticancer agents within 28 days of 5 half lives (whichever is the shorter duration) before the first administration of study drug. The exception is patients in Cohort 4 (PIK3CA-mutated breast cancer) are allowed to receive ongoing endocrine therapy.
  4. Have diabetes mellitus requiring insulin therapy
  5. Have diabetes mellitus requiring insulin secretagogue therapy
  6. Have poorly controlled diabetes mellitus defined as glycosylated (HbA1c) >7.5%
  7. Have a secondary requiring therapy or are unstable without therapy.
  8. Known impaired cardiac function or cardiac disease.
  9. Myocardial infarction or unstable angina within 6 months before the first administration of study drug.
  10. Pregnant (positive serum pregnancy test) or breastfeeding
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Serabelisib

    Part 1 is dose escalation of Serabelisib Cohort 1 = 600mg; Cohort 2 = 900mg; Cohort 3 = 1200mg Part 2 is expansion of mutational cohorts with selected dose as follows: Cohort 4 = PIK3CA-mutated breast cancer; Cohort 5 = PIK3CA-mutated Non breast cancer; Cohort 6 = KRAS mutated

    Drug: Serabelisib · Drug: Canagliflozin 300mg

Interventions

  • Subjects will be dosed with Serabelisib on 3 consecutive days a week in a 28 day cycle until tumor progression. in combination with Canagliflozin 300mg, both are oral medications

  • All subjects will be dosed with 300 mg canagliflozin in combination with serabelisib

    Also known as: Invokana

06

What researchers measure

Primary outcomes

  1. Rate of Adverse Events

    Safety of serabelisib in combination with canagliflozin as evaluated by incidence of drug-related adverse events (AEs), serious adverse events (SAEs), adverse events leading to discontinuation, deaths and clinical laboratory test abnormalities.

    Time frame: 30 days after last dose

  2. Rate of Laboratory Abnormalities

    Safety of serabelisib in combination with canagliflozin as evaluated by incidence of clinical laboratory abnormalities

    Time frame: 30 days after last dose

  3. Dose confirmation

    To confirm the appropriate dose of serabelisib to be coadministered with canagliflozin

    Time frame: 6 months

  4. Tumor Assessments by RESIST

    To assess efficacy of serabelisib in combination with canagliflozin in patients with solid tumors with PIK3CA or KRAS mutations

    Time frame: 2 years

Secondary outcomes

  1. Cmax Pharmacokinetic assessment

    Maximum observed plasma concentration (Cmax) of serabelisib

    Time frame: Day 1 and 8 of Cycle 1: pre-dose and then post-dose at 1.5 hours, 3 hours, 6 hours, 9 hours, 12 hours, and 24 hours

  2. Tmax Pharmacokinetic assessment

    Time of maximum observed plasma concentration (Tmax) of serabelisib

    Time frame: Day 1 and 8 of Cycle 1: pre-dose and then post-dose at 1.5 hours, 3 hours, 6 hours, 9 hours, 12 hours, and 24 hours

  3. AUC Pharmacokinetic assessment

    Area under the plasma concentration time curve in the dosing interval AUC of serabelisib

    Time frame: Day 1 and 8 of Cycle 1: pre-dose and then post-dose at 1.5 hours, 3 hours, 6 hours, 9 hours, 12 hours, and 24 hours

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2020; primary completion for Jul 2021, 10 months later.

Of 161 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's planned 10 months is below that.

Counting every sponsor, half of 328 studies reached it within 61 months; a quarter within 45 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2019
First posted
Aug 29, 2019
StartEst.
Sep 1, 2020
Primary completionEst.
Jul 15, 2021
CompletionEst.
Dec 30, 2021
Last update
May 21, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04073680
Lead sponsor
Petra Pharma
Responsible party
Sponsor
First posted
Aug 29, 2019
Start date
Sep 1, 2020 (estimated)
Primary completion
Jul 15, 2021 (estimated)
Completion
Dec 30, 2021 (estimated)
Last update
May 21, 2020

Study contacts

Albert Yu, MD
Contact
ayu@petrapharmacorp.com
646-440-9218
Peggy Siemon-Hryczyk, MS
Contact
psiemonh@petrapharmacorp.com
201-788-6161
Albert Yu, MD
study director · Petra Pharma

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Serabelisib

Start the discussion